ZielBio, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors (NCT05074472) | ZielBio, Inc. | 2022-01-14 |
Track ZielBio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.